These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1432918)

  • 21. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory issues for evaluation of therapies to prevent or arrest disease progression.
    Hyman FN; Welch ME; Cheever JR
    Ann Periodontol; 1997 Mar; 2(1):166-79. PubMed ID: 9151552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Food and drug administration approval process for dermatology drugs in the United States.
    Boozalis E; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug access. Unclogging the pipeline.
    Jenks S
    Med World News; 1989 Oct; 30(20):28-32, 34. PubMed ID: 10295988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA regulations for growth factors and related products.
    Chapekar MS; Gunter KC
    EXS; 1992; 61():471-8. PubMed ID: 1617242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemistry, manufacturing, and controls information in NDAs and ANDAs, supplements, annual reports, and other regulatory filings.
    Sheinin E; Williams R
    Pharm Res; 2002 Mar; 19(3):217-26. PubMed ID: 11934225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
    Hwang TJ; Franklin JM; Kesselheim AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modernizing the FDA: an incremental revolution.
    Merrill RA
    Health Aff (Millwood); 1999; 18(2):96-111. PubMed ID: 10091437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation.
    Khoruts A; Hoffmann DE; Palumbo FB
    J Law Med Ethics; 2019 Dec; 47(4):482-504. PubMed ID: 31957587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 37. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 39. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.